Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4491 - Metastatic Pancreatic Cancer: Real Life Data from the German Quality of Life and Translational Research on Pancreatic Cancer Study (QoliXane)

Date

09 Sep 2017

Session

Poster display session

Topics

Pancreatic Cancer

Presenters

Salah-Eddin Al-Batran

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

S. Al-Batran1, A. Reichart1, C. Schoenherr1, G. zur Hausen1, C. Pauligk1, B. Schöttger2, G. Siegler3, S. Doerfel4, A. Aldaoud5, L. Hahn6, J. Schubert7, O. Waidmann8, J. Trojan9, H. Hoeffkes10, R. Schnell11, M. Koenigsmann12, W. Blau13, J. Uhlig14, N. Homann15, T.O. Götze1

Author affiliations

  • 1 Institute Of Clinical Cancer Research (ikf), Nordwest-Krankenhaus, 60488 - Frankfurt am Main/DE
  • 2 Dept. Of Oncology, Onkopraxis, Würzburg/DE
  • 3 Dept. Of Oncology, Klinikum Nürnberg Nord, Nürnberg/DE
  • 4 Dept. Of Oncology, Dresden Onkozentrum, Dresden/DE
  • 5 Dept. Of Oncology, Gemeinschaftspraxis, 4289 - Leipzig/DE
  • 6 Gesellschaft Für Medizinische Studien Mbh Und Co. Kg, Praxis Dokusan, Herne/DE
  • 7 Dept. Of Oncology, Elblandklinik, 1589 - Riesa/DE
  • 8 Dept. Of Gastroenterology, Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), 60590 - Frankfurt am Main/DE
  • 9 Department Of Gastroenterology And Hepatology, University Hospital Frankfurt, Frankfurt/DE
  • 10 Dept. Of Oncology, Klinikum Fulda gAG, 36043 - Fulda/DE
  • 11 Oncology And Hematology, Praxis Internistischer Onkologie und Hämatologie (PIOH), 50226 - Frechen/DE
  • 12 Mediprojekt, Onkologisches Ambulanzzentrum OAZ, 30171 - Hannover/DE
  • 13 Dept. Of Oncology, Universitätsklinik Giessen, 35385 - Giessen/DE
  • 14 Oncological Practice, Oncological Practice, Naunhof/DE
  • 15 Dept. Of Gastroenterology And Oncology, Klinikum Wolfsburg, 38440 - Wolfsburg/DE
More

Resources

Abstract 4491

Background

Recently, nab-paclitaxel/gemcitabine (NPG) became new standard first-line therapy for metastatic pancreatic cancer. Based on this, our study group has established QoliXane for metastatic pancreatic cancer patients receiving 1st line NPG, to deliver real life and Quality of life (QoL) data and build a platform for translational research (TR). This is an interim analysis of our data focused on efficacy outcome.

Methods

In this a non-interventional registry study, eligible patients were recruited after written informed consent from 95 German cancer centers. The course of therapy, efficacy-, QoL- data (prior to and during therapy) and archival tumor material were prospectively collected. In the present analysis, efficacy endpoints were analyzed in the intention-to-treat population (ITT), defined as all patients who were enrolled.

Results

539 patients fulfilled the criteria of the ITT. Median age was 70 y (39-86). At the time of analysis, 301 (56%) pts of the ITT were alive. Mean no. of metastatic sites involved was 2. Median no. of cycles administered was 3 (range 0-6). 231 (43%) pts needed any dose modification and 209 (39%) received further therapies beyond progression. 70 (13%) pts had increased bilirubin at baseline, 18 (26%) of them had an intervention e.g. ERCP. Subjects with increased bilirubin without intervention received a median of 3 cycles, with decreasing values under therapy. 135 (25%) pts developed polyneuropathy of any grade. Median progression-free survival was 6 months (95% CI; [5- 6]). Median overall survival (OS) was 10 months (95% CI [8- 10]). 1-year OS was 40%. Median survivals by ECOG PS of 0, 1, 2, and 3 were 12 months, 9 months, 5 months, and 2 months, respectively (p

Conclusions

The “QoliXane” shows excellent real life efficacy data for 1st line therapy with NPG in Germany. In the expansion phase, QoliXane will transform into a permanent, high quality, prospective registry, covering all therapy lines. QoL and translational research data will follow.

Clinical trial identification

NCT02691052

Legal entity responsible for the study

Al- Batran

Funding

Celgene

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.